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Tumor microenvironment is a complex, multicellular functional compartment that, particularly when 
assembled as an abundant desmoplastic reaction, may profoundly affect the proliferative and 
invasive abilities of epithelial cancer cells. Tumor microenvironment comprises not only stromal cells, 
mainly cancer-associated fibroblasts, but also immune cells of both the innate and adaptive system 
(tumor-associated macrophages, neutrophils, natural killer cells, and T and B lymphocytes), and 
endothelial cells. This results in an intricate web of mutual communications regulated by an 
extensively remodeled extracellular matrix, where the tumor cells are centrally engaged. In this 
regard, cholangiocarcinoma, in particular the intrahepatic variant, has become the focus of mounting 
interest in the last years, largely due to the lack of effective therapies despite its rising incidence and 
high mortality rates worldwide. On the other hand, recent studies in pancreatic cancer, which 
similarly to cholangiocarcinoma, is highly desmoplastic, have argued against a tumor-promoting 
function of the tumor microenvironment. In this review, we will discuss recent developments 
concerning the role of each cellular population and their multifaceted interplay with the malignant 
biliary epithelial counterpart. We ultimately hope to provide the working knowledge on how their 
manipulation may lead to a therapeutic gain in cholangiocarcinoma. 
 
HIGHLIGHTS 
• Cholangiocarcinomas, including the intrahepatic and perihilar anatomical subtypes, are 
characterized by a prominent stromal reaction.  
• In cholangiocarcinoma, the tumor microenvironment is populated by a heterogeneous 
plethora of cells, including not only stromal cells (mainly cancer-associated fibroblasts), but 
also innate immune cells (tumor-associated macrophages, neutrophils), and adaptive 
immune cells (tumor-infiltrating lymphocytes).  
• Deciphering the complex interactions between malignant cholangiocytes and cells hosted in 
the tumor microenvironment is key to uncover novel therapeutic interventions targeting single 
cell compartments of the tumor microenvironment, in support of tumor cell–specific targeted 
therapies. 





The development of a highly reactive microenvironment in conjunction with the growth of the tumor 
mass is a functional hallmark of many epithelial cancers with pronounced invasiveness and shortage 
of therapeutic options (1). The tumor microenvironment is a heterogeneous, ‘multiethnic’ 
compartment, encompassing stromal cells, in particular activated fibroblasts (so-called cancer-
associated fibroblasts), and endothelial cells, along with a crowd of innate and adaptive immune 
cells (tumor-associated macrophages, neutrophils, natural killer cells, and T and B lymphocytes), 
which act in concert to provide tumor cells with a plethora of pro-invasive cues. In addition, 
extracellular matrix (ECM) degradation and remodeling support and encourage the reciprocal 
interactions among the different cell populations, thereby contributing to a pleomorphic milieu 
proficient to tumor growth and invasion. The result is the generation of a complex network of 
intercellular crosstalk. In other words, within this ‘ecosystem’, the non-malignant stromal and immune 
cell elements represent the ‘soil’ where the ‘seed’, namely the malignant epithelial counterpart, is not 
only hosted, but also nourished, aiding its engraftment and overgrowth (2).  
In cholangiocarcinoma (CCA), including both the intrahepatic and the perihilar anatomical subtypes, 
the extent of the tumor stroma is so prominent that it outweighs the tumoral component (3). Other 
epithelial malignancies of glandular origin, including breast, prostate, gastric and pancreatic 
adenocarcinomas, feature an abundant desmoplasia, but the effects can be different, depending on 
the specific disease context. Many studies highlighted the pro-tumorigenic role played by the tumor 
microenvironment, and the classic view supports the concept that targeting tumor stroma may offer 
a valuable strategy to halt tumor progression (4). In contrast with tumor cells, whose genetic 
heterogeneity makes response to conventional chemotherapy unpredictable, stromal and immune 
cells are not transformed, and thus, offer a therapeutic advantage, as they display a much more 
predictable response to therapy (5). From this point of view, anti-angiogenesis therapy, pioneered 
as an approach in some settings such as metastatic colorectal cancer, has shown to be effective (6). 
However, recent data derived from experimental models argue against the pro-invasive functions of 
the stromal reaction. In mouse models of pancreatic ductal adenocarcinoma, indeed, depletion of 
cancer-associated fibroblasts induced a more aggressive tumor phenotype and accelerated tumor 
spread with reduced survival, thus indicating that some stromal elements may act to restrain rather 
than stimulate tumor growth (7, 8). Alternatively, homeostatic restoration of the desmoplastic stroma 
by reprogramming fibroblasts into their quiescent state is an effective strategy to slow progression 
of pancreatic cancer (9, 10). The aim of this review is to clarify the role of the tumor microenvironment 
in CCA, and to understand if it can provide targets for therapeutic intervention. Therefore, we will 
examine the role of each cell compartment and its intricate interplay with the tumoral cells, at 
instances by highlighting results from other desmoplastic epithelial cancers, before discussing if their 




The role of cancer-associated fibroblasts in CCA 
A major cellular population of the desmoplastic stroma of CCA is represented by fibroblast-like cells, 
called cancer-associated fibroblasts (CAFs). These cells are activated myofibroblasts, expressing α-
smooth muscle actin (α-SMA) (Figure 1A) (11, 12). Most observations indicate that CAFs play a key 
role in mediating CCA growth and progression, as well as resistance to therapy. Hence, high α-SMA 
expression in the tumor stroma correlates with poor survival in patients with CCA (13, 14). Important 
evidence of their role was provided by the demonstration that triggering CAF apoptosis with the BH3 
mimetic navitoclax reduces tumor burden and metastasis in vivo in a syngeneic rat model of 
cholangiocarcinoma (15). 
Mechanisms underlying CAF recruitment 
CAFs constitute a phenotypically heterogeneous group of myofibroblasts, whose origin is still 
uncertain and probably multiple (2). For instance, distinct subpopulations of CAFs expressing 
specific cell surface markers such as podoplanin, a mucin-like transmembrane glycoprotein (16) or 
CD10, a cell surface metalloprotease (17), have been associated with lymphatic spread or with 
different anatomical location, respectively. Immunohistochemistry studies using cell-type specific 
markers have reported that these cells most likely originate from hepatic stellate cells (HSCs) (14) 
and/or portal fibroblasts (18, 19). Other potential cellular sources of CAFs include bone marrow-
derived mesenchymal cells, which are recruited from the peripheral blood (20). On the other hand, 
the contribution of epithelial-to-mesenchymal transition (EMT) of cholangiocytes to myofibroblasts 
has been refuted in murine models of liver fibrosis using lineage-tracing techniques (21-23). 
Furthermore, in vivo xenotransplant studies with CCA cells demonstrated that CAFs are not 
generated through an EMT process of CCA cells, but rather their recruitment was regulated via 
platelet-derived growth factor (PDGF)-D secretion by CCA cells. PDGF-D promotes fibroblast 
migration through its cognate receptor PDGFRβ, and activation of its downstream effectors, Rho 
GTPase and c-Jun N-terminal kinase (JNK) (24). In a murine model of breast cancer, also a highly 
desmoplastic tumor type, DNA damage in tumor cells during tumor initiation induces activation of 
fibroblasts via COX-2/prostaglandin E2 and activin-A (25). This pathway has not been explored in 
CCA. 
Cross-talk between CAF and tumor cells In the past years, the characterization of biliary epithelial 
cells and stromal cells from human surgical CCA resected specimens has provided new information 
on their crosstalk with CCA tumor cells and other immune cell types in the tumor stroma (24, 26). 
CAFs are pivotal in this context as they are able to communicate in a multi-directional manner with 
virtually every cell type in the tumor microenvironment (27). The molecular regulation of this 
communication is rather challenging to dissect due to its high level of complexity, plasticity and 
dynamics (28). CAFs are able to enhance the malignant phenotype of CCA cells via various soluble 
factors, e.g. hepatocyte growth factor (HGF), transforming growth factor (TGF)-β, connective tissue 
growth factor (CTGF), epidermal growth factor (EGF), stromal cell–derived factor-1 (SDF-1) and 
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angiotensin II, secreted in conjunction with major ECM components and matrix metalloproteases 
(MMPs) (11). In turn, CCA cells are capable of attracting and activating fibroblasts or myofibroblast 
precursor cells, e.g. via PDGF-D and TGF-β (24, 29). The presence of a reciprocal paracrine loop 
between CAFs and tumor epithelial cells mediated by the heparin-binding (HB) EGF/EGF receptor 
(EGFR) axis is paradigmatic of the intense two-ways communication by which CAFs sustain 
invasiveness of CCA cells and in turn, are persistently activated by them. CAFs produce HB-EGF, 
which activates EGFR, expressed by CCA cells. Following activation, EGFR signals via its 
downstream effectors, extracellular signal-regulated kinase (ERK) 1/2 and signal transducer and 
activator of transcription 3 (STAT3), leading to nuclear translocation of β-catenin, which unfolds a 
transcriptional program involved in cell motility and invasion (29). Activation of EGFR signaling also 
triggers TGF-β1 production by CCA cells, which further enhances myofibroblast activation and CAFs 
synthesis of HB-EGF (29). Similar to HB-EGF, CAF-derived SDF-1 stimulates CCA cell invasion 
acting via ERK1/2 and AKT upon binding to its receptor chemokine (C-X-C motif) receptor 4 
(CXCR4), and this effect is abrogated by the CXCR4 inhibitor AMD3100 (30). PDGF-B is another 
important paracrine signal emitted by CAFs and influencing CCA cell behavior. Once secreted by 
CAFs, PDGF-B interacts with its cognate receptor PDGFR-β expressed by CCA cells to induce tumor 
cell resistance to tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) by activating 
the Hedgehog signaling. This paracrine mechanism has translational relevance, as shown in an 
orthotopic syngeneic rat model of CCA, where Hedgehog inhibition by cyclopamine reduces tumor 
growth by stimulating CCA cell apoptosis (31). Recent data demonstrate that in addition to promoting 
CAFs accumulation within the tumor stroma, PDGF-D produced by CCA cells provides CAFs with 
pronounced pro-lymphangiogenic functions, mediated by secretion of vascular endothelial growth 
factor (VEGF)-A and VEGF-C, which induce the chemotaxis of lymphatic endothelial cells to gather 
in a proper vascular bed also favoring CCA cell intravasation (Figure 1C-D). Furthermore, in a 
syngeneic rat model of CCA, depletion of CAFs by navitoclax reduces the lymphatic vascularization 
of the tumor mass and more importantly, lymph node metastases in vivo (32). Accordingly, 
transcriptomic analysis of the tumor stroma in CCA found that a stromal signature enriched for TGF-
β and TNF receptor superfamiles, associated with a strong expression of pro-inflammatory 
mediators, significantly correlated with poor prognosis (33). Taken together, these findings point 
towards an important tumor-supporting role of CAFs already at very early time points during tumor 
evolution. 
 
Cross-talk between CAF and innate immune cells Beside cancer cells, CAFs communicate 
extensively with cells of the immune system, including tumor-associated macrophages (TAMs). 
Monocytes and macrophages are of critical importance for the activation of fibroblasts, as originally 
noted by Ross studying skin wound healing (34). In murine models of liver fibrosis, hepatic 
macrophages promote disease progression via nuclear factor k-light-chain-enhancer of activated B 
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cells (NF-kB)-dependent enhancement of HSC survival (35). In turn, CAFs have been shown to 
recruit macrophages in various murine and human tumors, thereby stimulating angiogenesis and 
tumor progression (36). While these results and the significant (molecular and cell biological) overlap 
between wound healing, fibrosis and tumor formation (37) argue for a significant role of the CAF-
macrophage axis in CCA, functional studies addressing this intriguing topic are missing. Besides 
cells of innate immunity, a large body of evidence supports a pivotal role of CAFs in the regulation 
of adaptive immunity in the tumor microenvironment. The vast array of cytokines, chemokines and 
pro-angiogenic factors secreted by CAFs, is believed to predominantly generate an 
immunosuppressive microenvironment (12). Compared with myofibroblasts, CAFs also express high 
levels of fibroblast activation protein (FAP), a membrane-bound serine protease implicated in ECM 
remodeling, and FAP overexpression has been reported in tumor stroma of highly invasive epithelial 
cancers, as pancreatic ductal adenocarcinoma (38). Interestingly, FAP expression identifies a subset 
of CAFs with upregulated expression of proinflammatory genes, which promotes 
immunosuppression by recruiting myeloid-derived stromal cells (MDSCs) in the tumor 
microenvironment via STAT3–CCL2 signaling (39). The immune-suppressive function of CAFs was 
convincingly demonstrated by immunogenic tumor (and stromal cell) necrosis in response to genetic 
ablation of a CAF-subset in murine pancreatic adenocarcinoma (40). Of note, two independent 
groups reported a rather unexpected tumor progression upon CAFs depletion in murine tumor 
models, demonstrating that the consequences of CAFs depletion are highly context-dependent (7, 
8). With respect to CCA, a small study analyzing immune-related transcripts in resected biliary tract 
cancers (BTCs) displayed a significant association between the expression of cytotoxic T-
lymphocyte antigen (CTLA)-4 and relapse-free survival (41). While these results are interesting and 
suggest an immunosuppressive environment promoting tumor progression, the functional relevance 
and molecular mechanisms of the cross-talk between CAFs and adaptive immune cells remains 
largely elusive in CCA. This topic will conceivably become of growing interest in the era of 
immunotherapy of solid tumors. 
 
Effects of CAF on ECM  
Alongside the multitude of soluble factors enabling communications with the different cell types that 
populate the tumor microenvironment, CAFs produce major ECM components, such as tenascin C 
and periostin, and secrete several MMPs. Coupled with those released by the cancer cells 
themselves, MMPs are essential to degrade and remodel the ECM, as pre-requisite for tumor 
progression. In CCA, CAFs express MMP1, MMP2, MMP3, and MMP9 and this phenotype is 
associated with tumors that are more aggressive (42, 43). However, recent data indicate that in 
desmoplastic tumor microenvironments, CAFs can make passageways in the ECM in an MMP-
independent manner. The basement membrane is the barrier that at the stage of carcinoma in situ, 
segregates tumor cells from the stroma, and it must be broken to let tumor cell spread through the 
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surrounding tissues. In addition to proteolysis, rupturing of the basement membrane can be favored 
by fine CAF movements dependent upon their overdeveloped contractility. By pulling and stretching 
the basement membrane, CAFs exert mechanical forces which soften the barrier integrity and lead 
to the formation of gaps permissive for cancer cell migration and invasion, as elegantly shown in an 
ex vivo model of colorectal cancer (44). 
 
The evolving role of the ECM in CCA 
As discussed above, in intrahepatic and peri-hilar CCA, neoplastic bile ducts are tightly surrounded 
by an abnormally remodeled and stiff ECM, which contributes to tumor invasiveness and 
progression. Similar to the epithelial part, the ECM gradually undergoes a phenotypic switch from a 
thin layer beneath the basal side of the normal biliary epithelium into a thick and rigid structure 
favoring tumor duct interactions with many stromal and immune cells (2). The native structure of 
ECM is perturbed by deposition of new structural components and its concurrent dismantlement by 
proteases, either secreted by cell types recruited in the tumor microenvironment, in particular CAFs, 
TAMs, as well as by the tumoral cells themselves (23). Some major ECM constituents, such as 
tenascin-C, osteopontin, and periostin, are newly synthetized in CCA, where they promote key tumor 
properties, as invasive cell growth, chemoresistance, and metastatic spread (45, 46). Moreover, their 
overexpression, mainly at the invasive front as in the case of tenascin-C, correlates with an increase 
in tumor size, lymph node metastatization, and a worsen outcome (46). Periostin, in particular, has 
drawn increasing interest as a potential prognostic biomarker and putative molecular target in the 
intrahepatic variant of CCA (iCCA) (45). Periostin is a glycoprotein belonging to the TGF-β family-
inducible matricellular proteins, extensively represented also in the ECM of other desmoplastic 
epithelial cancers, as reported in pancreatic ductal adenocarcinoma (47). In desmoplastic tumors, 
CAFs are the main cell source of periostin. In malignant cholangiocytes, periostin interacts with other 
ECM components, particularly collagen type I and tenascin-C, and with integrins, particularly α5β1, 
α5β3, α5β5, and α6β4, leading to activation of a proliferative cascade mediated by phosphoinositide 
3-kinase (PI3K)/AKT signaling (48). Of note, CCA cells express the periostin receptor, the α5 subunit 
of integrin, and knockdown of α5 integrin decreased tumor proliferation and invasion (49). Gene 
expression profiling of laser-capture microdissected stroma obtained from human iCCA revealed two 
additional ECM components, laminin and osteopontin, that besides being markedly up-regulated 
compared with non-tumor tissue, had also strong clinical relevance as they significantly correlated 
with poor prognosis (50). In particular, stromal overexpression of osteopontin and TGF-β2 were the 
most significant independent predictors in terms of both overall and disease free survival (50). The 
‘desmoplastic’ ECM can play a pro-tumorigenic effect also thanks to its increased rigidity. External 
mechanical forces induce cells to change the tension and the structure of the cytoskeleton, exerting 
potent tumor suppressor functions in normal epithelia. Two intracellular mechanosensors, Yes-
associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), are 
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particularly sensitive to ECM stiffening and act as fundamental supervisors of both tissue repair 
mechanisms and tumor initiation and progression by regulating crucial cell functions, including 
proliferation, survival, plasticity, and invasion (51). Once activated in tumor epithelial cells by nuclear 
translocation and interaction with the transcription factor TEAD, YAP/TAZ elicit a number of pro-
invasive pathways, such as the mTOR/cyclin D1-mediated hyper-proliferation, the AKT-mediated 
escape from apoptosis, and the activation of the EMT program endowing tumoral cells with 
mesenchymal properties (52). Recent data show that alternative to association with TEAD, YAP/TAZ 
nuclear activity is inhibited by its association with the switching defective/sucrose non-fermenting 
(SWI/SNF) chromatin-remodeling complex through ARID1A (53), whose genetic inactivation has 
been reported in about 7% of iCCA (54). The association between ARID1A–SWI/SNF and YAP/TAZ 
is finely regulated by cellular mechanotransduction: whereas soft ECM favors YAP/TAZ inhibitory 
sequestration within the ARID1A-containing SWI/SNF, conversely stiff ECM induces YAP/TAZ 
detachment from SWI/SNF and their binding to TEAD (53). Notably, a stiff ECM enhances the activity 
of YAP/TAZ not only in cancer cells but also in stromal cells, including CAFs. Active nuclear YAP 
was expressed by CAFs, and YAP depletion in CAFs reduced their tumor-promoting functions. In 
breast cancer, ECM stiffening regulates a feed-forward self-reinforcing loop that helps to maintain 
the CAFs phenotype by sustaining YAP activation. In turn, YAP controls the expression of 
cytoskeletal regulators, including ANLN and DIAPH3, and of the myosin light chain 9 (MYL9) that 
regulates CAFs contractility and motility (55).  
 
The role of the innate immune system in CCA 
Several innate immune cells encompassing macrophages, neutrophils, and natural killer (NK) cells 
are present in the tumor microenvironment and they significantly affect cholangiocarcinogenesis 
(Figure 1B). Tumor-associated macrophages (TAMs) are the most relevant infiltrating immune cell 
population within the tumor microenvironment (56). High tissue macrophage density has been 
associated with poor prognosis of patients with CCA (57). Furthermore, circulating CD14+/CD16+ 
monocyte levels correlate with TAM infiltration and are associated with poor prognosis (58). CCA 
cells induce macrophage polarization toward the alternatively activated macrophage or M2 
phenotype via the STAT3 pathway, these being associated with bad prognosis in patients with CCA 
(59). Macrophages, through their crosstalk with CCA cells participate in tumor growth by releasing a 
variety of inflammatory, growth, and proliferative factors (60-62). 
Elevated preoperative peripheral blood neutrophil-to-lymphocyte (NLR) ratio is also a poor 
prognostic factor for intrahepatic and extrahepatic CCA (63-66), as well as in patients with advanced 
CCA undergoing chemotherapy (67, 68). Distribution of tumor-associated neutrophils (TAN) in CCA 
tissue sections by immunohistochemical analysis of CD15, a marker of mature granulocytes, has 
revealed that patients with high CD15 expression have shorter disease free survival time and overall 
survival than those with low expression (69). Moreover, neutrophil gelatinase-associated lipocalin 
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(NGAL) expression in bile has been identified as a valuable candidate to discern malignant from 
benign biliary strictures (70).  
NK cells are innate lymphocytes with the capacity to recognize and eliminate tumor cells via the 
release of cytotoxic granules (71). This recognition is regulated by a plethora of activating and 
inhibitory immune receptors expressed on the surface of NK cells. With these, NK cells can sense 
and respond to ‘stressed’ cells, such as cancer cells, in the nearby area (71). The liver is enriched 
in NK cells compared with other lymphocytes and they represent up to 30-40% of all liver 
lymphocytes (72). Despite this, little is known regarding NK cells in CCA. Instead, more studies have 
been performed in HCC where several immune receptors expressed by NK cells, such as CD96 and 
NKp30, have been associated with better prognosis (73, 74). Furthermore, immunotherapy with 
infusion of activated allogeneic NK cells have also been performed in HCC patients with promising 
outcomes (75, 76). However, before such treatments can be employed in CCA, it is necessary to 
determine if NK cells have the capacity to infiltrate CCA, which NK cell receptor–ligand interactions 
are important for recognition of CCA, and how NK cells are affected by evasion strategies employed 
by the tumor and its microenvironment. 
 
Mechanisms underlying innate immune cell recruitment The mechanisms underpinning the 
complex innate immune response in CCA are still largely unknown. As mentioned above, 
macrophage polarization towards the tumor-promoting M2 state is associated with poor prognosis 
and metastasis in CCA (77). TAMs are a subtype of M2 macrophages with particular powerful tumor-
promoting functions (78) and derive mainly from CD14+/CD16+ circulating monocytes rather than 
from resident macrophages; indeed, the massive expansion of intrahepatic macrophages observed 
during chronic liver injury follows the influx of circulating monocytes (79). Monocyte recruitment into 
the liver is promoted by chemoattractant molecules, including monocyte chemoattractant protein-1 
(MCP-1/CCL2), colony stimulating factor (CSF)-1, and VEGF-A (80). Notably intrahepatic 
macrophages are an important source of CCL2 that stimulates the migration of bone marrow-derived 
monocytes (81). Further, macrophage recruitment is supported by epithelial tumor cells and CAFs, 
and is also stimulated by regulatory pathways (Notch, IL6/STAT3, PI3K) and specific cytokines (IL1β, 
IL10, IL13, and IL4) (82). In CCA, a stem cell-like compartment is particularly active in promoting 
recruitment of circulating monocytes along with their differentiation into TAMs, by releasing IL13, 
IL34, and osteoactivin. Importantly, TAMs associated with the cancer stem cell niche display unique 
features, including expression of both M1 and M2 phenotypic traits, increased adhesive and invasive 
capabilities, in vitro, and enhanced tumor-promoting activities, in vivo (83). This has lent support to 
the notion that different TAM subsets are present within the tumor, reflecting different hints derived 
from various cell niches. Finally, TAMs themselves modulate the CCA microenvironment by 




Infiltration of TANs has also been associated with poor prognosis in CCA (69). Recruitment of 
neutrophils in CCA is predominantly driven by CXCL5, which has direct chemoattractant effects on 
TANs in vitro through PI3K-AKT and ERK1/2 signaling pathways (84). TANs expressing CCL2 and 
CCL17 recruit TAMs and regulatory T lymphocytes, eventually generating an immunosuppressive 
environment, which sustains tumor promotion. 
As aforementioned, CAFs are highly active in recruiting innate immune cells, and can play a dual 
role with both tumor-suppressive and tumor-promoting potential that may be partly explained by the 
regulatory state(s) and heterogeneity of CAFs. Beside recruiting immunosuppressive MDSCs and 
TAMs (39), CAFs attract and educate dendritic cells (DCs) into a regulatory state, attenuating the 
expression of antigen-presenting HLA molecules, reducing the capability to attract and activate 
tumor infiltrating lymphocytes (85), and enhancing the ability of MDSCs to inhibit T cell proliferation 
via FAP/STAT3/CCL2 axis (39). 
 
Mechanisms whereby innate immune system influences tumor growth  
Well in line with the above outlined heterogeneity and complexity of innate immune cells in tumor 
microenvironment, the mechanisms by which these cells impinge on tumor progression are diverse. 
TAMs are able to accelerate tumor progression on multiple levels. They take part in tumoral 
angiogenesis via the secretion of pro-angiogenic (e.g. VEGF-A, angiopoietin, IL8) and pro-
inflammatory mediators, such as cyclooxygenase (COX)-2 and inducible nitric oxide synthase 
(iNOS), supporting tumor growth beyond the limits of oxygen and nutrient diffusion (86). Additionally, 
macrophage-derived Wnt ligands, such as Wnt3a and Wnt7b, activate canonical Wnt pathway, 
contributing to CCA cell proliferation (61, 62). Thus, macrophage depletion or Wnt signaling inhibition 
halts tumor growth in vitro and in experimental models recapitulating CCA (61, 62). Furthermore, 
TAMs are able to dampen the efficacy of anti-proliferative drugs against solid tumors in a substantial 
manner. Certain chemotherapeutic agents, e.g. doxorubicin, enhance TAM accumulation in the 
tumor microenvironment, ultimately attenuating their cytotoxic effects (87). Although the molecular 
underpinnings are still enigmatic (88), recent work by Lyssiotis’ group showed that in murine models 
of pancreatic ductal adenocarcinoma, pyrimidine species released by TAMs inhibit gemcitabine via 
functional interference with drug uptake and metabolism (89). This suggests that TAM metabolism 
is interwoven with that of cancer cells with the potential to modulate the therapeutic response of solid 
tumors. Anti-tumor immunity is another paramount effect played by TAMs. TAMs can suppress 
tumor-inhibiting T cells via different mechanisms, e.g. via depletion of essential metabolic precursors 
such as L-arginine (90) by hypoxia-mediated upregulation of arginase and iNOS (91).  
Within the macrophage population, the TIE2-expressing monocytes/macrophages (TEMs) represent 
a myeloid cell subset found in blood as well as in tumor tissue with relevance for tumor progression. 
TIE-2 is the receptor for angiopoietins, and TEMs are indeed highly pro-angiogenic (92). 
Furthermore, TEMs, via IL10, suppress T cell proliferation, increase the CD4/CD8 ratio, and support 
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the expansion of CD4+CD25highFOXP3+ regulatory T lymphocytes (Tregs), highlighting TEMs as a 
vigorous immunosuppressive force in the tumor microenvironment (93). However, in CCA TEM 
abundance is associated with improved prognosis, suggesting additional, hitherto unknown 
mechanisms by which TEMs inhibit tumor progression (94). 
In the innate immune system, NK cells are of pivotal importance given their ability to control microbial 
infections and tumor progression (71, 95, 96). Phenotypically, NK cells are defined as CD3−CD56+ 
lymphocytes in humans and as CD3−NK1.1+ lymphocytes in mice. Lysis of target cells, including 
neoplastic cells, is the hallmark function of NK cells and of paramount importance for their tumor-
inhibiting efficacy (71). Anti-tumor effects of NK cells can be overcome by various means, e.g. 
conservation of MHC class I (MHC-I) expression, shedding of ligands for the activating NK receptor 
(e.g. NKG2DLs), and secretion of immunomodulatory molecules (e.g. TGF-β, prostaglandin E2, 
adenosine) by tumor cells, ultimately resulting in tumor progression (71). Interestingly, under defined 
conditions, NK cells can express programmed cell death protein-1 (PD-1) and CTLA-4, which are 
instrumental for anti-tumor T cell responses and represent targets for several approved 
immunotherapy agents (97). The functional relevance of NK cells for CCA is only beginning to 
emerge. In vitro, activated NK cells have been shown to enhance the cytotoxic efficacy of cetuximab 
against human CCA cell lines (98), while in vivo, infusion of ex vivo-expanded human NK cells in 
HuCCT-1 xenografts in nude mice displayed significant tumor-inhibiting effects (99). 
 
The role of adaptive immune system in CCA 
Convincing evidence in both mouse models and human patients support the ability of the adaptive 
immune system to identify and target arising tumor cells, and thus, to behave as a primary defense 
against cancer (100). Tumor-infiltrating lymphocytes (TILs) are present in many solid tumors and 
form highly heterogeneous populations (101). While TILs can act against tumor cells to inhibit 
carcinogenesis and to hamper cancer progression (‘immune surveillance’), cancer cells devise 
stratagems to circumvent anti-cancer immune reactions and boost tumor progression (‘immune 
escape’) (102, 103). Tumor infiltrates include B lymphocytes, CD8+ cytotoxic T lymphocytes, cytokine 
secreting CD4+ T helper lymphocytes, and Forkhead box P3 (FoxP3)+ Tregs. Additionally, DCs as 
an important bridge between adaptive and innate immune responses are abundant in the tumor 
microenvironment and shuffle antigen towards the draining lymph node for immune activation (104).   
In CCA, CD8+ T lymphocytes have been studied in terms of presence and location within the tumor. 
Overall, CD4+ TILs prevail in the peritumoral region (105), while CD8+ TILs are mostly prevalent in 
the intratumoral tissue (105, 106). More than half of resected CCAs are positive for CD8+ TILs, of 
which 30% are reported positive for Granzyme B, indicating an activated and cytotoxic phenotype 
(107). Multiple studies confirm that enhanced CD4+ and CD8+ infiltrates (also in combination with 
low numbers of macrophages) in CCA and extrahepatic BTCs are associated with better overall 
survival, fewer lymph node metastases and reduced venous and perineural invasion (106-110), 
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whereas low numbers of CD8+ TILs are associated with poor overall survival (111). In addition, MHC-
I expression in intrahepatic and extrahepatic CCA strongly correlates with the CD4+ and CD8+ tumor 
infiltrate and is associated with longer overall survival (112). Consistent with these findings, in BTCs, 
the total count of lymphocytes of the adaptive immune response showed a stepwise decrease in 
invasive and metastatic tumors compared with non-invasive precursors (106), suggesting a 
gradually developing immune escape of the tumor.  
The number of CD4+ and CD8+ lymphocytes in CCA tissue may additionally be influenced by DCs. 
It has been demonstrated that immature CD1a+ DCs reside only in the tumor core, while mature 
CD83+ DCs are found predominantly at the invasive front (110). Moreover, the number of DCs at the 
invasive margin correlated with the number of CD4+ and CD8+ TILs in the tumor bulk. Additionally, 
mature DCs surrounded by CD4+ and CD8+ cells are observed at the cancer periphery, highlighting 
the importance of immune cell interactions in CCA. A similar finding was reported in colorectal 
carcinoma, indicating that these clusters of DCs and T lymphocytes are formed to maximize T cell 
activation against the tumor (110, 113). Takagi suggested a direct link between the abundance of 
mature DCs able to prime anti-tumor T cells at the invasive margin and the risk of cancer invasion 
and metastasis (110). Indeed, they could show that CD4+ and CD8+ T cell infiltration in the cancerous 
tissue is enhanced by mature CD83+ DCs at the tumor-host interface of CCA, with CD83+ patients 
displaying a better prognosis and lower incidence of lymph node metastases than CD83− patients 
(110). Furthermore, patients classified with an advanced tumor stage showed significantly lower 
numbers of either immature or mature DCs. 
While several studies have drawn attention to T cells, the role of B lymphocytes in CCA is still far 
from clear. B cells have been identified in TIL populations in BTC, but they are only rarely observed 
in patient tissues (105, 106). Albeit high densities of CD20+ cells have been observed in low-grade 
tumors and associate with a favorable overall survival (106), future studied are needed to clarify their 
relevance. 
 
Mechanisms of immune surveillance and immune escape 
The presence of immunogenic tumor-associated antigens has been demonstrated in CCA patients 
(114). Importantly, the cytotoxic reaction is balanced by immunosuppressive signals. Indeed, CCL2 
secreted by tumor cells, TAMs, and CAFs, stimulates tumor-infiltrating T cells to acquire CD4/CD25 
expression and become Tregs (115). Tumor-associated Tregs secrete IL10 and TGF-β, which inhibit 
cytotoxic T cells and NK cells and shape an immunosuppressive milieu. Further, Tregs bind IL2, 
making it unavailable in the tumor microenvironment and thus preventing the activation of additional 
immune cells (116). A recent study confirmed that CCA cells also activate natural Treg-like 
CD4+CD25− cells, leading to an increased expression of TGF-β, which suppresses the immune 
response (117). TGF-β is overexpressed in CCA, and correlates with poor prognosis, lymph node 
and distant metastases, and tumor recurrence (118). However, TGF-β signaling also conveys a 
16 
 
tumor-suppressing influence by inhibiting tumor growth in the early stage of malignant transformation 
(119).  
FoxP3 is a distinctive feature of Tregs but it is overexpressed also by tumor cells (120). Knockdown 
of FoxP3 in tumor cells in vitro reduced proliferation and invasiveness in CCA cells, inhibited T cell 
survival, and reduced IL10 and TGF-β signaling in the tumor microenvironment (120). Consequently, 
FoxP3 overexpression correlates with lymphatic metastasis, poor survival and shorter disease-free 
survival (111, 120). Furthermore, FoxP3 overexpression is accompanied by CTLA-4 overexpression 
(41). Indeed, CTLA-4 is expressed on the surface of Tregs and has to bind to CD80 on antigen-
presenting cells to exert inhibitory effects on cytotoxic cells (112). Interestingly, a deregulation of 
genes related to immune modulation in BTCs was more pronounced in the peritumoral than in the 
tumor tissue and facilitated tumor recurrence and chemo-resistance. Strong CD80 expression, likely 
reflecting the enrichment of activated Tregs in the microenvironment, correlated with resistance to 
adjuvant chemotherapy. Furthermore, the expression of CTLA4 in the peritumoural area has 
prognostic value highlighting the concept that immune escape in CCA associates with poor 
prognosis (41).  
In order to evade immune surveillance as mechanism of resistance, cancer cells frequently 
manipulate immune checkpoints such as PD-1 and CTLA-4, that once activated by their specific 
ligands (PD-L1 and CD152, respectively), promote peripheral T cell exhaustion. High expression of 
PD-L1 among other immune checkpoints and of tumor-specific neoantigens characterized a subset 
of CCA patients (5.9%, 14/239) with high mutational load and poor prognosis (121). Both PD-1 and 
PD-L1 are up-regulated in neoplastic cells (122-124), and overexpression is associated with 
increased invasiveness, poor outcome, and worse disease- and metastasis-free survival, especially 
when accompanied by low CD3+ or CD8+ infiltrate (109, 122, 125, 126). Conversely, low PD-L1 
expression (in combination with high MHC-I expression) was found to be related to favorable 
prognosis (127). Consequently, the PD-L1/PD-1 pathway might be responsible, to some extent, for 
lymphocyte apoptosis in CCA progression and account for an increased cancer’s malignant 
potential.  
Notch signaling, an important morphogen in the liver, and a signaling mechanism associated with 
iCCA (128, 129), can also modulate the immune cell regulation necessary for activation of T-helper 
1 cells (130) and CD4+FoxP3+ Tregs (131). In addition, Notch may contribute to M1 polarization of 
macrophages and to their relationships with CAFs. Since Notch is also involved in T cell induction 
and in stimulating T cell effector secretory functions (IL10, IL22, and IFN-γ), it is tempting to 
hypothesize that Notch is crucial for directing T cell infiltrates in CCA (130, 131). 
The interaction between the immune system and the neoplastic epithelial cells: lesson from 
the lymphoepithelioma-like CCA  
The lymphoepithelioma-like CCA (LEL-CCA) is a variant of iCCA with distinct epidemiological, 
morphological, and clinical features. So far, 40 cases have been described, the majority in women 
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from South-East Asia. In spite of this rarity, LEL-CCA is of interest because it represents a peculiar 
model of interaction between the immune and neoplastic compartment, and is characterized by 
significantly superior overall survival when compared with classical iCCA of corresponding stage 
(132-134). Histologically, LEL-CCA consists of undifferentiated epithelial cells and dense polyclonal 
lymphocyte infiltrate but in absence of a typical stromal reaction. Tumour cells are arranged in sheets 
and express the pankeratin A1/A3 and the biliary type cytokeratin K7 and K19 (135); markers of 
stemness such as CD133 and EpCAM are frequently expressed. The lymphoid infiltrate includes 
CD3+ and, to a lesser extent, CD20+ cells, and interestingly, metastatic lesions of LEL-CCA lose the 
lymphoid component. Epstein-Barr virus (EBV) non coding RNA (EBER) is present in almost all 
cases (136). Although genetic changes of LEL-CCA are unknown, the ability of EBV to induce 
epigenetic changes resulting in cell proliferation and oncogenesis is well recognized. Accordingly, 
LEL-CCA is characterized by DNA hypermethylation, in particular of cellular retinol binding protein-I 
(CRBPI) and of cellular retinol binding protein-IV (CRBPIV), significantly more frequent than in 
classical iCCA (132). The type of EBV latency in LEL-CCA has been elucidated only in part. EBERs 
were positive in almost all cases, latency membrane proteins-1 and -2 (LMP1 and LMP2) were 
negative in eight tested samples, and LMP-related gene showed a 30 bp deletion in two tested cases 
(137, 138). Thus, similar to nasopharyngeal carcinoma, the expression of EBV-related antigens and 
tumour genetics might drive the lymphocyte recruitment. Expression of PD-L1 has been studied in 
LEL-CCA and compared with iCCA, showing a much higher rate in LEL-CCA in both tumor and 
tumor-infiltrating cells, though the latter were not specifically phenotyped (124, 139). In theory, these 
findings challenge the hypothesis that PD-L1 is associated with a poor prognosis. However, in 
lymphoepithelioma-like hepatocellular carcinoma (LEL-HCC), where strong PD-L1 expression was 
similarly reported, the infiltrating cells mostly consist of T cells, and the ratio of CD8+ to FoxP3+ Treg 
cells is high (140), suggesting that in this setting, a favourable long-term outcome is not at odds with 
an up-regulation of PD-L1. It remains to be evaluated whether the same holds true in LEL-CCA. 
 
Modulating each single cell compartment for therapeutic gain in iCCA 
In the last years, technological advances such as next-generation sequencing (NGS) have unraveled 
the high genomic and transcriptomic heterogeneity of iCCA, uncovering promising molecular targets 
for therapeutic intervention (121, 141, 142). While therapy targeting the cancer cells becomes 
increasingly more individualized, the contribution of the tumor microenvironment especially in highly 
desmoplastic tumors appears now clearer. The number of molecular biomarkers derived from each 
cell compartment of the tumor microenvironment holding prognostic value in CCA are summarized 
in Table 1. Furthermore, given the uniform reactive phenotype, the tumor stroma is additionally, an 
attractive therapeutic target. In this regard, promising strategies include molecular targeting of 
tumor cells, CAFs, immune cells, and vascular cells (Table 2). Among tumor cell targeted therapy, 
we will discuss only those related to fibroblast growth factor receptor (FGFR) mutations as 
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recently turned-out to be potentially relevant also for the modulation of the microenvironment. A 
comprehensive review of the novel mutation-based tumor cell targeted strategies are outlined in 
the specific chapter of the present special issue, which the reader may eventually refer to. 
Tumor cell targeted therapy Within the last decade, the knowledge of molecular subtypes of CCA 
expanded remarkably. Identification of druggable targets and candidate molecules is gaining traction 
based on NGS. Exploiting FGFR mutations in CCA is one of the most advanced, promising 
approaches, together with therapies directed against EGFR, especially Her-2 mutations and IDH 
directed treatments. Whole-exome sequencing of predominantly liver fluke-negative, hepatitis virus-
negative iCCAs by the Cancer Genome Atlas (TCGA) identified inactivating mutations in tumor 
suppressor genes, including ARID1A, ARID1B, BAP1, TP53, and PTEN as well as gain-of-function 
mutations in the oncogenes IDH1, IDH2, BRAF, and KRAS (143). Interestingly, focal losses of 
CDKN2A, encoding p16INK4A, which inhibits the cyclin-dependent kinases CDK4 and CDK6 were 
observed and at a substantially higher proportion (up to 15%) than reported previously (121, 141). 
Receptor-tyrosine-kinase inhibitors (TKIs) Advanced stage solid malignancies, including iCCA are 
included into several selective and nonselective FGFR inhibitors for early phase clinical trials (143). 
Pan-FGFR inhibitors as NVP-BGJ398 and erdafitinib showed potential as well manageable safety 
profiles (144, 145). NVP-BGJ398 showed impressive results by a disease control rate of 82% (146) 
and tumor-activity results of erdafitinib from the ongoing phase II trial (NCT02699606) will be 
presented soon (147). Panatinib, another non-selective TKIs showed promising efficacy for FGFR2 
fusions in patients with iCCA (148) and is currently evaluated in an ongoing phase II trial 
(NCT02265341). Several early phase I and phase II studies with selective FGFR-inhibitors including 
iCCA are ongoing like derazantinib (NCT01752920), TAS-120 (NCT02052778), Debio 1347 
(NCT01948297), and INCB054828 (NCT02924376, NCT02393248). 
Recently, an elegant experimental study shows that FGFR inhibition causes cell necrosis in human 
CCA cells, downregulating the expression of the myeloid cell leukemia 1 (Mcl1), a member of the 
Bcl-2 family of anti-apoptotic proteins. Necrosis is caused by the cellular depletion of Mcl1 within the 
mitochondrial matrix which impairs mitochondrial functions. Notably, cell death by necrosis induced 
by FGFR inhibition may be synergic for either chemotherapy, dampening intrinsic anti-apoptotic 
cellular resistance of CCA, or immunotherapy, by eliciting a strong immunological antitumor 
response (149).   
 
Manipulation of CAFs 
CAFs isolated from CCA patients show an enhanced susceptibility to apoptosis which results from 
an imbalance of Bcl-2 family members. Of note, the pro-apoptotic drug navitoclax, an inhibitor of Bcl-
2, Bcl-xL, and Bcl-w, selectively induces apoptosis in CAFs and reduces tumor growth, as well as 
peritoneal and lymph node metastasis in a syngeneic rat model of CCA (15, 34). Moreover, A-
1331852, a specific inhibitor for Bcl-xL, is able to induce apoptosis in activated fibroblasts and 
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reduces biliary fibrosis in a mouse model of primary sclerosing cholangitis (150), a pre-malignant 
condition of CCA. Thus, these data strongly support selective deletion of CAFs with Bcl-2 inhibitors 
as a therapeutic strategy in CCA. 
 
Immunotherapy 
Self-tolerance and protection of normal tissue during immune responses is maintained by immune 
checkpoints. These immune checkpoints are frequently altered by cancer cells to escape immune 
surveillance. Restoring the immune response to evoke anti-tumor immunity is a promising new 
approach in cancer therapy. As previously mentioned, two molecules are of special interest in this 
regard. CTLA-4 and PD-1/PD-L1 inhibitor are established for cancer immunotherapy. Studies of 
molecular phenotyping showed that immune checkpoint molecules are up-regulated in 45 % of BTCs 
(121). Further studies found overexpression of PD-1/PD-L1 in iCCA (122). Interestingly, tumors with 
immune checkpoint dysregulation showed less differentiated histology and more advanced tumor 
stage with worse outcome (127). However, data on immunotherapy in CCA are still scarce. The anti-
PD-1 antibody pembrolizumab is under investigation in a phase II trial (NCT02628067). Preliminary 
data show promising efficacy in CCA with about 40% response rate. The PD-L1 inhibitor nivolumab 
has just been approved for HCC while data for CCA are still missing.  
Besides immune checkpoint inhibitors, adoptive cell immunotherapy is a novel approach. Genetic 
reprogramming of autologous immune cells aims to enhance tumor cell recognition and anti-tumor 
immune response. Chimeric antigen receptor (CAR) T-cell therapy is one of the latest development 
approaches in this field. So far there are no adoptive immune cell therapies under clinical 
investigation for CCA. 
 
Angiogenesis inhibitors  
Although proangiogenic factors such as VEGF, are expressed in 50% of iCCA (151), the clinical 
relevance of angiogenesis inhibitors in iCCA remains controversial. A clinical phase II trial using 
bevacizumab, a humanized antibody targeting VEGF-A, in combination with gemcitabin and 
oxaliplatin (GEMOX), demonstrated a partial response in 41% of patients (152). Sorafenib, a tyrosine 
kinase inhibitor acting on VEGF receptors (VEGFR) and PDGFRs, reduced tumor growth in iCCA 
mouse models (153) but failed in clinical trials as single agent therapy or in combination with 
chemotherapy (154, 155). To further explain the disappointment with angiogenesis inhibitors it must 
be underlined that quite surprisingly, the main route of CCA dissemination through the lymphatic 
vascular system has not been considered yet for selective targeting (156). Interestingly, in a 
xenograft model of iCCA, targeting VEGFR-3 receptor (cognate of the main lymphangiogenic growth 
factor VEGF-C) markedly reduced tumor-associated lymphangiogenesis (34). Further investigations 
should also focus on the identification of CCA subgroups (e.g. patients with enhanced PDGF-BB 





Studies in animal models and human samples have expanded the concept of the tumor 
microenvironment as a functional component central to tumorigenesis and tumor progression 
especially in epithelial cancers featuring an exuberant desmoplastic reaction. Within the multiple cell 
elements populating the microenvironment, new actors in particular from the immune system, have 
been added to the formerly characterized CAFs and TAMs, and make the interplay among them and 
with the tumor cells extremely intricate. Consequently, recent observations have argued against the 
original view that combinatorial interactions between different factors released in the tumor 
microenvironment boost the pervasive phenotype of cancer cells. Here we have dissected the 
pleomorphic functions of stromal and immune reactions in CCA (summarized in Figure 2). In this 
regard, LEL-CCA is paradigmatic of the protective role played by the immune milieu and this model 
will deserve strong attention by future studies aimed at testing efficacy of immunotherapy. On the 
other hand, very recent studies have further validated the pro-invasive functions exerted by stromal 
cells, showing that besides directly supporting the proliferative and invasive potential of cancer cells, 
CAFs provide them with a rich lymphatic vasculature instrumental for their early dissemination. 
Indeed, CAF depletion has led to significant anti-tumor effects in CCA. However, the considerable 
heterogeneity of CCA requires a multimodal, multiagent therapy that besides including tumor-
promoting stromal cells, will gain traction from high throughput screening of target molecules and 
NGS-based stratification of patients, to identify and explore new effective and more personalized 
therapeutic approaches (157). 
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Figure 1. Spatial relationships of different cell types in the tumor microenvironment of CCA. 
Immunohistochemistry for α-SMA (A), CD45 (B), CD34 (C), and dual immunohistochemistry for α-
SMA (brown) and podoplanin (blue) (D) of formalin-fixed paraffin-embedded tissue sections obtained 
from surgical specimens of a patient with intrahepatic CCA undergoing liver resection. A) Cancer-
associated fibroblasts identified by their immunoreactivity for α-SMA form a tight shell around the 
malignant bile ducts. B) Innate inflammatory cells expressing CD45 (neutrophils, macrophages, NK 
cells) are located in close vicinity to a large vascular space (*) consistent with their recruitment into 
the tumor microenvironment from the circulating compartment. C) Blood endothelial cells positive for 
CD34 are rarely observed nearby the neoplastic bile ducts, compared with D) the numerous 
podoplanin+ lymphatic endothelial cells laying strictly adjacent to α-SMA+ cancer-associated 
fibroblasts in between the tumoral ducts. A-C counterstained with DAPI. Original magnification: 200x. 
Figure 2. Main features enabling the tumor microenvironment proficient to tumor growth and 
invasion in CCA. Compared with the normal stroma (upper side of the cartoon), the tumor 
microenvironment undergoes significant structural changes which profoundly affect the proliferative 
and invasive abilities of tumor cholangiocytes. The rupturing of the basement membrane (BM) allows 
invasive cholangiocytes to get access to a dense infiltrate comprising, among many cell types, 
activated cancer-associated fibroblasts (CAF), M2-polarized tumor-associated macrophages (TAM), 
regulatory T lymphocytes (Treg), and newly assembled lymphatic vessels through which tumor cells 
can early disseminate. A stiff extracellular matrix (ECM) provides support for the reciprocal 





1. BANALES J M, CARDINALE V, CARPINO G, et al. Expert consensus document: Cholangiocarcinoma: 
current knowledge and future perspectives consensus statement from the European Network for the Study 
of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 2016; 13(5): 261-80. 
2. CADAMURO M, STECCA T, BRIVIO S, et al. The deleterious interplay between tumor epithelia and 
stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018; 1864(4 Pt B): 1435-43. 
3. RIZVI S, GORES G J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. 
Gastroenterology 2013; 145(6): 1215-29. 
4. MERTENS J C, RIZVI S, GORES G J. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis 
Dis 2018; 1864(4 Pt B): 1454-60. 
5. GREAVES M, MALEY C C. Clonal evolution in cancer. Nature 2012; 481(7381): 306-13. 
6. DOUILLARD J Y, RONG A, SIDHU R. RAS mutations in colorectal cancer. N Engl J Med 2013; 369(22): 
2159-60. 
7. RHIM A D, OBERSTEIN P E, THOMAS D H, et al. Stromal elements act to restrain, rather than 
support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25(6): 735-47. 
8. OZDEMIR B C, PENTCHEVA-HOANG T, CARSTENS J L, et al. Depletion of carcinoma-associated 
fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. 
Cancer Cell 2014; 25(6): 719-34. 
9. SHERMAN M H, YU R T, ENGLE D D, et al. Vitamin D receptor-mediated stromal reprogramming 
suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014; 159(1): 80-93. 
10. FROELING F E, KOCHER H M. Homeostatic restoration of desmoplastic stroma rather than its 
ablation slows pancreatic cancer progression. Gastroenterology 2015; 148(4): 849-50. 
11. SIRICA A E. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat 
Rev Gastroenterol Hepatol 2011; 9(1): 44-54. 
12. KALLURI R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016; 16(9): 582-98. 
13. CHUAYSRI C, THUWAJIT P, PAUPAIROJ A, CHAU-IN S, SUTHIPHONGCHAI T, THUWAJIT C. Alpha-
smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival 
in cholangiocarcinoma. Oncol Rep 2009; 21(4): 957-69. 
14. OKABE H, BEPPU T, HAYASHI H, et al. Hepatic stellate cells may relate to progression of intrahepatic 
cholangiocarcinoma. Ann Surg Oncol 2009; 16(9): 2555-64. 
15. MERTENS J C, FINGAS C D, CHRISTENSEN J D, et al. Therapeutic effects of deleting cancer-associated 
fibroblasts in cholangiocarcinoma. Cancer Res 2013; 73(2): 897-907. 
16. AISHIMA S, NISHIHARA Y, IGUCHI T, et al. Lymphatic spread is related to VEGF-C expression and D2-
40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod Pathol 2008; 21(3): 256-64. 
17. NISHIHARA Y, AISHIMA S, HAYASHI A, et al. CD10+ fibroblasts are more involved in the progression 
of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma. 
Histopathology 2009; 55(4): 423-31. 
18. DRANOFF J A, WELLS R G. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. 
Hepatology 2010; 51(4): 1438-44. 
19. ITOU R A, UYAMA N, HIROTA S, et al. Immunohistochemical characterization of cancer-associated 
fibroblasts at the primary sites and in the metastatic lymph nodes of human intrahepatic 
cholangiocarcinoma. Hum Pathol 2018. 
20. RUSSO F P, ALISON M R, BIGGER B W, et al. The bone marrow functionally contributes to liver 
fibrosis. Gastroenterology 2006; 130(6): 1807-21. 
21. SCHOLTEN D, OSTERREICHER C H, SCHOLTEN A, et al. Genetic labeling does not detect epithelial-to-
mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 2010; 139(3): 987-98. 
22. CHU A S, DIAZ R, HUI J J, et al. Lineage tracing demonstrates no evidence of cholangiocyte 
epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology 2011; 53(5): 1685-
95. 
23. VAQUERO J, GUEDJ N, CLAPERON A, NGUYEN HO-BOULDOIRES T H, PARADIS V, FOUASSIER L. 
Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. J 
Hepatol 2017; 66(2): 424-41. 
23 
 
24. CADAMURO M, NARDO G, INDRACCOLO S, et al. Platelet-derived growth factor-D and Rho GTPases 
regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013; 58(3): 1042-
53. 
25. FORDYCE C A, PATTEN K T, FESSENDEN T B, et al. Cell-extrinsic consequences of epithelial stress: 
activation of protumorigenic tissue phenotypes. Breast Cancer Res 2012; 14(6): R155. 
26. HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-74. 
27. GENTILINI A, PASTORE M, MARRA F, RAGGI C. The Role of Stroma in Cholangiocarcinoma: The 
Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. Int J Mol 
Sci 2018; 19(10). 
28. GASCARD P, TLSTY T D. Carcinoma-associated fibroblasts: orchestrating the composition of 
malignancy. Genes Dev 2016; 30(9): 1002-19. 
29. CLAPERON A, MERGEY M, AOUDJEHANE L, et al. Hepatic myofibroblasts promote the progression of 
human cholangiocarcinoma through activation of epidermal growth factor receptor. Hepatology 2013; 
58(6): 2001-11. 
30. GENTILINI A, ROMBOUTS K, GALASTRI S, et al. Role of the stromal-derived factor-1 (SDF-1)-CXCR4 
axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J Hepatol 2012; 57(4): 813-
20. 
31. FINGAS C D, BRONK S F, WERNEBURG N W, et al. Myofibroblast-derived PDGF-BB promotes 
Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011; 54(6): 2076-88. 
32. CADAMURO M, BRIVIO S, MERTENS J, et al. Platelet-Derived Growth Factor-D Enables Liver 
Myofibroblasts to Promote Tumor Lymphangiogenesis in Cholangiocarcinoma. J Hepatol 2018. 
33.  ANDERSEN JB, SPEE B, BLECHACZ BR, et al. Genomic and genetic characterization of 
cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 
142(4):1021-31. 
34. ROSS R, BENDITT E P. Wound healing and collagen formation. I. Sequential changes in components 
of guinea pig skin wounds observed in the electron microscope. J Biophys Biochem Cytol 1961; 11: 677-700. 
35. PRADERE J P, KLUWE J, DE MINICIS S, et al. Hepatic macrophages but not dendritic cells contribute 
to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013; 58(4): 
1461-73. 
36. EREZ N, TRUITT M, OLSON P, ARRON S T, HANAHAN D. Cancer-Associated Fibroblasts Are Activated 
in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. 
Cancer Cell 2010; 17(2): 135-47. 
37. DVORAK H F. Tumors: wounds that do not heal-redux. Cancer Immunol Res 2015; 3(1): 1-11. 
38. FEIG C, JONES J O, KRAMAN M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated 
fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 2013; 
110(50): 20212-7. 
39. YANG X, LIN Y, SHI Y, et al. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in 
the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res 2016; 76(14): 4124-35. 
40. KRAMAN M, BAMBROUGH P J, ARNOLD J N, et al. Suppression of antitumor immunity by stromal 
cells expressing fibroblast activation protein-alpha. Science 2010; 330(6005): 827-30. 
41. GHIDINI M, CASCIONE L, CAROTENUTO P, et al. Characterisation of the immune-related 
transcriptome in resected biliary tract cancers. Eur J Cancer 2017; 86: 158-65. 
42. TERADA T, OKADA Y, NAKANUMA Y. Expression of immunoreactive matrix metalloproteinases and 
tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 
1996; 23(6): 1341-4. 
43. PRAKOBWONG S, YONGVANIT P, HIRAKU Y, et al. Involvement of MMP-9 in peribiliary fibrosis and 
cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer 2010; 127(11): 
2576-87. 
44. GLENTIS A, OERTLE P, MARIANI P, et al. Cancer-associated fibroblasts induce metalloprotease-
independent cancer cell invasion of the basement membrane. Nat Commun 2017; 8(1): 924. 
45. SIRICA A E, ALMENARA J A, LI C. Periostin in intrahepatic cholangiocarcinoma: pathobiological 
insights and clinical implications. Exp Mol Pathol 2014; 97(3): 515-24. 
24 
 
46. AISHIMA S, TAGUCHI K, TERASHI T, MATSUURA S, SHIMADA M, TSUNEYOSHI M. Tenascin 
expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma. Mod 
Pathol 2003; 16(10): 1019-27. 
47. BEN Q W, JIN X L, LIU J, CAI X, YUAN F, YUAN Y Z. Periostin, a matrix specific protein, is associated 
with proliferation and invasion of pancreatic cancer. Oncol Rep 2011; 25(3): 709-16. 
48. UTISPAN K, SONONGBUA J, THUWAJIT P, et al. Periostin activates integrin alpha5beta1 through a 
PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. Int J Oncol 2012; 41(3): 1110-8. 
49. BARIL P, GANGESWARAN R, MAHON P C, et al. Periostin promotes invasiveness and resistance of 
pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. 
Oncogene 2007; 26(14): 2082-94. 
50.  SULPICE L, RAYAR M, DESILLE M, et al. Molecular profiling of stroma identifies osteopontin as an 
independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013; 58(6):1992-
2000. 
51. HALDER G, DUPONT S, PICCOLO S. Transduction of mechanical and cytoskeletal cues by YAP and 
TAZ. Nat Rev Mol Cell Biol 2012; 13(9): 591-600. 
52. ZANCONATO F, CORDENONSI M, PICCOLO S. YAP/TAZ at the Roots of Cancer. Cancer Cell 2016; 
29(6): 783-803. 
53.  CHANG L, AZZOLIN L, DI BIAGIO D, et al. The SWI/SNF complex is a mechanoregulated inhibitor of 
YAP and TAZ. Nature 2018; 563(7730): 265-69. 
54. ZOU S, LI J, ZHOU H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun 
2014; 5: 5696. 
55. CALVO F, EGE N, GRANDE-GARCIA A, et al. Mechanotransduction and YAP-dependent matrix 
remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 
2013; 15(6): 637-46. 
56. BRIVIO S, CADAMURO M, STRAZZABOSCO M, FABRIS L. Tumor reactive stroma in 
cholangiocarcinoma: The fuel behind cancer aggressiveness. World J Hepatol 2017; 9(9): 455-68. 
57. SUBIMERB C, PINLAOR S, KHUNTIKEO N, et al. Tissue invasive macrophage density is correlated with 
prognosis in cholangiocarcinoma. Mol Med Rep 2010; 3(4): 597-605. 
58. SUBIMERB C, PINLAOR S, LULITANOND V, et al. Circulating CD14(+) CD16(+) monocyte levels predict 
tissue invasive character of cholangiocarcinoma. Clin Exp Immunol 2010; 161(3): 471-9. 
59. HASITA H, KOMOHARA Y, OKABE H, et al. Significance of alternatively activated macrophages in 
patients with intrahepatic cholangiocarcinoma. Cancer Sci 2010; 101(8): 1913-9. 
60. TECHASEN A, LOILOME W, NAMWAT N, DOKDUANG H, JONGTHAWIN J, YONGVANIT P. Cytokines 
released from activated human macrophages induce epithelial mesenchymal transition markers of 
cholangiocarcinoma cells. Asian Pac J Cancer Prev 2012; 13 Suppl: 115-8. 
61. LOILOME W, BUNGKANJANA P, TECHASEN A, et al. Activated macrophages promote Wnt/beta-
catenin signaling in cholangiocarcinoma cells. Tumour Biol 2014; 35(6): 5357-67. 
62. BOULTER L, GUEST R V, KENDALL T J, et al. WNT signaling drives cholangiocarcinoma growth and 
can be pharmacologically inhibited. J Clin Invest 2015; 125(3): 1269-85. 
63. BUETTNER S, SPOLVERATO G, KIMBROUGH C W, et al. The impact of neutrophil-to-lymphocyte ratio 
and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery 2018; 
164(3): 411-18. 
64. CHEN Q, YANG L X, LI X D, et al. The elevated preoperative neutrophil-to-lymphocyte ratio predicts 
poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy. Tumour Biol 2015; 
36(7): 5283-9. 
65. KITANO Y, YAMASHITA Y I, YAMAMURA K, et al. Effects of Preoperative Neutrophil-to-Lymphocyte 
and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma. 
Anticancer Res 2017; 37(6): 3229-37. 
66. TAN D W, FU Y, SU Q, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic 
Outcomes of Cholangiocarcinoma: A Meta-analysis. Sci Rep 2016; 6: 33789. 
67. LEE B S, LEE S H, SON J H, et al. Neutrophil-lymphocyte ratio predicts survival in patients with 
advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother 2016; 65(2): 141-50. 
25 
 
68. HA H, NAM A R, BANG J H, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-
lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative 
chemotherapy. Oncotarget 2016; 7(47): 76604-12. 
69. MAO Z Y, ZHU G Q, XIONG M, REN L, BAI L. Prognostic value of neutrophil distribution in 
cholangiocarcinoma. World J Gastroenterol 2015; 21(16): 4961-8. 
70. BUDZYNSKA A, NOWAKOWSKA-DULAWA E, MAREK T, BOLDYS H, NOWAK A, HARTLEB M. 
Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-
associated lipocalin. J Physiol Pharmacol 2013; 64(1): 109-14. 
71. MORVAN M G, LANIER L L. NK cells and cancer: you can teach innate cells new tricks. Nat Rev 
Cancer 2016; 16(1): 7-19. 
72. BJORKSTROM N K, LJUNGGREN H G, MICHAELSSON J. Emerging insights into natural killer cells in 
human peripheral tissues. Nat Rev Immunol 2016; 16(5): 310-20. 
73. MANTOVANI S, OLIVIERO B, LOMBARDI A, et al. Deficient natural killer cell NKp30-mediated 
function and altered NCR3 splice variants in hepatocellular carcinoma. Hepatology 2018. 
74. SUN H, HUANG Q, HUANG M, et al. Human CD96 correlates to NK cell exhaustion and predicts the 
prognosis of human hepatocellular carcinoma. Hepatology 2018. 
75. ALNAGGAR M, LIN M, MESMAR A, et al. Allogenic Natural Killer Cell Immunotherapy Combined with 
Irreversible Electroporation for Stage IV Hepatocellular Carcinoma: Survival Outcome. Cell Physiol Biochem 
2018; 48(5): 1882-93. 
76. XIE S, WU Z, ZHOU L, et al. Iodine-125 seed implantation and allogenic natural killer cell 
immunotherapy for hepatocellular carcinoma after liver transplantation: a case report. Onco Targets Ther 
2018; 11: 7345-52. 
77. THANEE M, LOILOME W, TECHASEN A, et al. Quantitative changes in tumor-associated M2 
macrophages characterize cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer 
Prev 2015; 16(7): 3043-50. 
78. NOY R, POLLARD J W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 
2014; 41(1): 49-61. 
79. ZIMMERMANN H W, SEIDLER S, NATTERMANN J, et al. Functional contribution of elevated 
circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS 
One 2010; 5(6): e11049. 
80. MANTOVANI A, GERMANO G, MARCHESI F, LOCATELLI M, BISWAS S K. Cancer-promoting tumor-
associated macrophages: new vistas and open questions. Eur J Immunol 2011; 41(9): 2522-5. 
81. KARLMARK K R, WASMUTH H E, TRAUTWEIN C, TACKE F. Chemokine-directed immune cell 
infiltration in acute and chronic liver disease. Expert Rev Gastroenterol Hepatol 2008; 2(2): 233-42. 
82. HOGDALL D, LEWINSKA M, ANDERSEN J B. Desmoplastic Tumor Microenvironment and 
Immunotherapy in Cholangiocarcinoma. Trends Cancer 2018; 4(3): 239-55. 
83. RAGGI C, CORRENTI M, SICA A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating 
niche by educating associated macrophages. J Hepatol 2017; 66(1): 102-15. 
84. ZHOU S L, DAI Z, ZHOU Z J, et al. CXCL5 contributes to tumor metastasis and recurrence of 
intrahepatic cholangiocarcinoma by recruiting infiltrative intratumoral neutrophils. Carcinogenesis 2014; 
35(3): 597-605. 
85. CHENG J T, DENG Y N, YI H M, et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing 
regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis 2016; 5: e198. 
86. HENZE A T, MAZZONE M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest 
2016; 126(10): 3672-79. 
87. DENARDO D G, BRENNAN D J, REXHEPAJ E, et al. Leukocyte complexity predicts breast cancer 
survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1(1): 54-67. 
88. MITCHEM J B, BRENNAN D J, KNOLHOFF B L, et al. Targeting tumor-infiltrating macrophages 
decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. 
Cancer Res 2013; 73(3): 1128-41. 
89. HALBROOK C J, PONTIOUS C, LEE H-J, et al. Macrophage Released Pyrimidines Inhibit Gemcitabine 
Therapy in Pancreatic Cancer. bioRxiv 2018: 463125. 
26 
 
90. BRONTE V, ZANOVELLO P. Regulation of immune responses by L-arginine metabolism. Nat Rev 
Immunol 2005; 5(8): 641-54. 
91. DOEDENS A L, STOCKMANN C, RUBINSTEIN M P, et al. Macrophage expression of hypoxia-inducible 
factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 2010; 70(19): 7465-
75. 
92. DE PALMA M, MURDOCH C, VENNERI M A, NALDINI L, LEWIS C E. Tie2-expressing monocytes: 
regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28(12): 519-24. 
93. COFFELT S B, CHEN Y Y, MUTHANA M, et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to 
suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011; 186(7): 4183-90. 
94. ATANASOV G, HAU H M, DIETEL C, et al. Prognostic significance of TIE2-expressing monocytes in 
hilar cholangiocarcinoma. J Surg Oncol 2016; 114(1): 91-8. 
95. TALMADGE J E, MEYERS K M, PRIEUR D J, STARKEY J R. Role of natural killer cells in tumor growth 
and metastasis: C57BL/6 normal and beige mice. J Natl Cancer Inst 1980; 65(5): 929-35. 
96. GORELIK E, WILTROUT R H, OKUMURA K, HABU S, HERBERMAN R B. Role of NK cells in the control 
of metastatic spread and growth of tumor cells in mice. Int J Cancer 1982; 30(1): 107-12. 
97. BENSON D M, JR., BAKAN C E, MISHRA A, et al. The PD-1/PD-L1 axis modulates the natural killer cell 
versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. 
Blood 2010; 116(13): 2286-94. 
98. MORISAKI T, UMEBAYASHI M, KIYOTA A, et al. Combining cetuximab with killer lymphocytes 
synergistically inhibits human cholangiocarcinoma cells in vitro. Anticancer Res 2012; 32(6): 2249-56. 
99. JUNG I H, KIM D H, YOO D K, et al. In Vivo Study of Natural Killer (NK) Cell Cytotoxicity Against 
Cholangiocarcinoma in a Nude Mouse Model. In Vivo 2018; 32(4): 771-81. 
100. ZOU W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. 
Nat Rev Cancer 2005; 5(4): 263-74. 
101. FRIDMAN W H, PAGES F, SAUTES-FRIDMAN C, GALON J. The immune contexture in human tumours: 
impact on clinical outcome. Nat Rev Cancer 2012; 12(4): 298-306. 
102. KIM R, EMI M, TANABE K. Cancer immunoediting from immune surveillance to immune escape. 
Immunology 2007; 121(1): 1-14. 
103. GOODEN M J, DE BOCK G H, LEFFERS N, DAEMEN T, NIJMAN H W. The prognostic influence of 
tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 
105(1): 93-103. 
104. VON ANDRIAN U H, MEMPEL T R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 
2003; 3(11): 867-78. 
105. KASPER H U, DREBBER U, STIPPEL D L, DIENES H P, GILLESSEN A. Liver tumor infiltrating 
lymphocytes: comparison of hepatocellular and cholangiolar carcinoma. World J Gastroenterol 2009; 
15(40): 5053-7. 
106. GOEPPERT B, FRAUENSCHUH L, ZUCKNICK M, et al. Prognostic impact of tumour-infiltrating 
immune cells on biliary tract cancer. Br J Cancer 2013; 109(10): 2665-74. 
107. OSHIKIRI T, MIYAMOTO M, SHICHINOHE T, et al. Prognostic value of intratumoral CD8+ T 
lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 2003; 84(4): 
224-8. 
108. MIURA T, YOSHIZAWA T, HIRAI H, et al. Prognostic Impact of CD163+ Macrophages in Tumor 
Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct Cancer. Anticancer Res 
2017; 37(1): 183-90. 
109. LIM Y J, KOH J, KIM K, et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-
infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing 
surgery plus adjuvant chemoradiotherapy. Radiother Oncol 2015; 117(1): 165-70. 
110. TAKAGI S, MIYAGAWA S, ICHIKAWA E, et al. Dendritic cells, T-cell infiltration, and Grp94 expression 
in cholangiocellular carcinoma. Hum Pathol 2004; 35(7): 881-6. 
111. KITANO Y, OKABE H, YAMASHITA Y I, et al. Tumour-infiltrating inflammatory and immune cells in 
patients with extrahepatic cholangiocarcinoma. Br J Cancer 2018; 118(2): 171-80. 
27 
 
112. GOEPPERT B, FRAUENSCHUH L, ZUCKNICK M, et al. Major histocompatibility complex class I 
expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J 
Cancer 2015; 113(9): 1343-9. 
113. SUZUKI A, MASUDA A, NAGATA H, et al. Mature dendritic cells make clusters with T cells in the 
invasive margin of colorectal carcinoma. J Pathol 2002; 196(1): 37-43. 
114. KIDA A, MIZUKOSHI E, TAMAI T, et al. Immune responses against tumour-associated antigen-
derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients. Liver Int 2018; 38(11): 2040-50. 
115. WHITESIDE T L. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 
2012; 22(4): 327-34. 
116. VIVIER E, UGOLINI S, BLAISE D, CHABANNON C, BROSSAY L. Targeting natural killer cells and natural 
killer T cells in cancer. Nat Rev Immunol 2012; 12(4): 239-52. 
117. QIAN Y, YAO W, YANG T, et al. aPKC-iota/P-Sp1/Snail signaling induces epithelial-mesenchymal 
transition and immunosuppression in cholangiocarcinoma. Hepatology 2017; 66(4): 1165-82. 
118. WANG H, LI C, JIAN Z, OU Y, OU J. TGF-beta1 Reduces miR-29a Expression to Promote 
Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4. PLoS One 2015; 10(10): 
e0136703. 
119. MU X, PRADERE J P, AFFO S, et al. Epithelial Transforming Growth Factor-beta Signaling Does Not 
Contribute to Liver Fibrosis but Protects Mice From Cholangiocarcinoma. Gastroenterology 2016; 150(3): 
720-33. 
120. MA C, PENG C, LU X, et al. Downregulation of FOXP3 inhibits invasion and immune escape in 
cholangiocarcinoma. Biochem Biophys Res Commun 2015; 458(2): 234-9. 
121. NAKAMURA H, ARAI Y, TOTOKI Y, et al. Genomic spectra of biliary tract cancer. Nat Genet 2015; 
47(9): 1003-10. 
122. YE Y, ZHOU L, XIE X, JIANG G, XIE H, ZHENG S. Interaction of B7-H1 on intrahepatic 
cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion. J Surg 
Oncol 2009; 100(6): 500-4. 
123. ZHU Y, WANG X Y, ZHANG Y, et al. Programmed death ligand 1 expression in human intrahepatic 
cholangiocarcinoma and its association with prognosis and CD8(+) T-cell immune responses. Cancer Manag 
Res 2018; 10: 4113-23. 
124. FONTUGNE J, AUGUSTIN J, PUJALS A, et al. PD-L1 expression in perihilar and intrahepatic 
cholangiocarcinoma. Oncotarget 2017; 8(15): 24644-51. 
125. WALTER D, HERRMANN E, SCHNITZBAUER A A, et al. PD-L1 expression in extrahepatic 
cholangiocarcinoma. Histopathology 2017; 71(3): 383-92. 
126. MA K, WEI X, DONG D, WU Y, GENG Q, LI E. PD-L1 and PD-1 expression correlate with prognosis in 
extrahepatic cholangiocarcinoma. Oncol Lett 2017; 14(1): 250-56. 
127. SABBATINO F, VILLANI V, YEARLEY J H, et al. PD-L1 and HLA Class I Antigen Expression and Clinical 
Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res 2016; 22(2): 470-8. 
128. FAN B, MALATO Y, CALVISI D F, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J 
Clin Invest 2012; 122(8): 2911-5. 
129. DILL M T, TORNILLO L, FRITZIUS T, et al. Constitutive Notch2 signaling induces hepatic tumors in 
mice. Hepatology 2013; 57(4): 1607-19. 
130. BURGHARDT S, ERHARDT A, CLAASS B, et al. Hepatocytes contribute to immune regulation in the 
liver by activation of the Notch signaling pathway in T cells. J Immunol 2013; 191(11): 5574-82. 
131. BURGHARDT S, CLAASS B, ERHARDT A, KARIMI K, TIEGS G. Hepatocytes induce Foxp3(+) regulatory 
T cells by Notch signaling. J Leukoc Biol 2014; 96(4): 571-7. 
132. LABGAA I, VILLACORTA-MARTIN C, D'AVOLA D, et al. A pilot study of ultra-deep targeted 
sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018; 37(27): 
3740-52. 
133. LABGAA I, STUECK A, WARD S C. Lymphoepithelioma-Like Carcinoma in Liver. Am J Pathol 2017; 
187(7): 1438-44. 
134. SOLINAS A, CALVISI D F. Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas. 
World J Gastroenterol 2015; 21(12): 3472-9. 
28 
 
135. CHEN T C, NG K F, KUO T. Intrahepatic cholangiocarcinoma with lymphoepithelioma-like 
component. Mod Pathol 2001; 14(5): 527-32. 
136. JENG Y M, CHEN C L, HSU H C. Lymphoepithelioma-like cholangiocarcinoma: an Epstein-Barr virus-
associated tumor. Am J Surg Pathol 2001; 25(4): 516-20. 
137. SUN K, XU S, WEI J, et al. Clinicopathological features of 11 Epstein-Barr virus-associated 
intrahepatic cholangiocarcinoma at a single center in China. Medicine (Baltimore) 2016; 95(40): e5069. 
138. HUANG Y, TSUNG J S, LIN C W, CHENG T Y. Intrahepatic cholangiocarcinoma with 
lymphoepithelioma-like carcinoma component. Ann Clin Lab Sci 2004; 34(4): 476-80. 
139. WANG L, DONG H, NI S, et al. Programmed death-ligand 1 is upregulated in intrahepatic 
lymphoepithelioma-like cholangiocarcinoma. Oncotarget 2016; 7(43): 69749-59. 
140. CHAN A W, TONG J H, PAN Y, et al. Lymphoepithelioma-like hepatocellular carcinoma: an 
uncommon variant of hepatocellular carcinoma with favorable outcome. Am J Surg Pathol 2015; 39(3): 304-
12. 
141. ROSS J S, WANG K, GAY L, et al. New routes to targeted therapy of intrahepatic 
cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19(3): 235-42. 
142. SIRICA A E, GORES G J, GROOPMAN J D, et al. Intrahepatic Cholangiocarcinoma: Continuing 
Challenges and Translational Advances. Hepatology 2018. 
143. RIZVI S, KHAN S A, HALLEMEIER C L, KELLEY R K, GORES G J. Cholangiocarcinoma - evolving concepts 
and therapeutic strategies. Nat Rev Clin Oncol 2018; 15(2): 95-111. 
144. RIZVI S, YAMADA D, HIRSOVA P, et al. A Hippo and Fibroblast Growth Factor Receptor Autocrine 
Pathway in Cholangiocarcinoma. J Biol Chem 2016; 291(15): 8031-47. 
145. PERERA T P S, JOVCHEVA E, MEVELLEC L, et al. Discovery and Pharmacological Characterization of 
JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. Mol Cancer Ther 
2017; 16(6): 1010-20. 
146. JAVLE M M, SHROFF R T, ZHU A, et al. A phase 2 study of BGJ398 in patients (pts) with advanced or 
metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based 
chemotherapy. J Clin Oncol 2016; 34(4). 
147. TABERNERO J, BAHLEDA R, DIENSTMANN R, et al. Phase I Dose-Escalation Study of JNJ-42756493, 
an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin 
Oncol 2015; 33(30): 3401-8. 
148. BORAD M J, CHAMPION M D, EGAN J B, et al. Integrated genomic characterization reveals novel, 
therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic 
cholangiocarcinoma. PLoS Genet 2014; 10(2): e1004135. 
149. KABASHIMA A, HIRSOVA P, BRONK S F, et al. Fibroblast growth factor receptor inhibition induces 
loss of matrix MCL1 and necrosis in cholangiocarcinoma. J Hepatol 2018; 68(6): 1228-38. 
150. MONCSEK A, AL-SURAIH M S, TRUSSONI C E, et al. Targeting senescent cholangiocytes and activated 
fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene 
knockout (Mdr2(-/-) ) mice. Hepatology 2018; 67(1): 247-59. 
151. YOSHIKAWA D, OJIMA H, IWASAKI M, et al. Clinicopathological and prognostic significance of EGFR, 
VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98(2): 418-25. 
152. ZHU A X, MEYERHARDT J A, BLASZKOWSKY L S, et al. Efficacy and safety of gemcitabine, oxaliplatin, 
and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET 
with clinical outcome: a phase 2 study. Lancet Oncol 2010; 11(1): 48-54. 
153. SUGIYAMA H, ONUKI K, ISHIGE K, et al. Potent in vitro and in vivo antitumor activity of sorafenib 
against human intrahepatic cholangiocarcinoma cells. J Gastroenterol 2011; 46(6): 779-89. 
154. EL-KHOUEIRY A B, RANKIN C J, BEN-JOSEF E, et al. SWOG 0514: a phase II study of sorafenib in 
patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 
2012; 30(4): 1646-51. 
155. LEE J K, CAPANU M, O'REILLY E M, et al. A phase II study of gemcitabine and cisplatin plus sorafenib 
in patients with advanced biliary adenocarcinomas. Br J Cancer 2013; 109(4): 915-9. 
156. PELLINO A, LOUPAKIS F, CADAMURO M, et al. Precision medicine in cholangiocarcinoma. Transl 
Gastroenterol Hepatol 2018; 3: 40. 
29 
 
157. CHAITEERAKIJ R, HARMSEN W S, MARRERO C R, et al. A new clinically based staging system for 














In situ malignant cholangiocyte
Dismantled BM
Figure 2
Table 1. Tumor microenvironment-related biomarkers with prognostic relevance in CCA 
when increasingly expressed. 




Prognostic correlation Ref. 
α-SMA CAF Cytoskeletal protein Reduced survival 13,14 











FAP CAF Membrane-bound 
serine protease 
implicated in ECM 
remodeling 











Reduced survival 42,57 
Periostin CAF and ECM TGF-β-inducible 
matricellular 
glycoprotein 
Reduced survival and 
increased metastatic spread 
45 
Tenascin-C ECM Developmental 
matricellular 
glycoprotein 




Laminin ECM Developmental 
matricellular 
glycoprotein, major 
component of the 
basement membrane 
Reduced survival 50 
Osteopontin ECM Integrin-binding 
matricellular 
glycoprotein 
Reduced survival  50 
MAC387 
(S100A8/9)  
TAM S100 calcium-binding 
proteins 
Reduced survival 57 
CD14/CD16 Circulating 
monocytes 
CD14 – LPS co-
receptor 
CD16 – FCγIII receptor 
Reduced survival 58 
CD15 TAN Glycan determinant or 
Lewis x 
Reduced survival 69 
CD163 TAM High affinity scavenger 







TIE2 TAM Receptor for 
angiopoietins 
Improved survival 94 
CD4/CD8  TIL (T helper 
and T cytotoxic 
lymphocytes) 
CD4 – surface 
glycoprotein co-
receptor of TCR and 
MHC-class II 
CD8 – surface 
glycoprotein co-
receptor of TCR and 
MHC-class I 
Improved survival, reduced 
lymphatic metastasis, 
reduced venous and 
perineural invasion  
106-
110 





expressed by B-cells 
through maturation 
Low-grade differentiation 
tumors, improved survival 
106 
CD83 DC Integral membrane 
protein belonging to the 
Ig superfamily involved 
in antigen presentation 
Improved survival, reduced 
lymphatic metastasis  
110 
TGF-β Tumor stroma Pro-fibrogenic cytokine Reduced survival, increased 




FoxP3 Treg and 
tumor cells 
Member of the 
forkhead transcription 
factor family promoting 
immunosuppressive 
functions 





CTLA-4 Treg Surface protein binding 
to CD80 on antigen-
presenting cells to 
inhibit cytotoxic cells 
Reduced survival, increased 
lymphatic metastasis 
41 
PD-1, PD-L1 Tumor cells Immune check-point 
molecules 
Reduced survival, increased 





CAF, cancer-associated fibroblasts 
CTLA-4, cytotoxic T-lymphocyte antigen-4 
DC, dendritic cells 
ECM, extracellular matrix 
PD-1, programmed cell death protein-1 
PD-L1, programmed death-ligand 1 
TAM, tumor-associated macrophages 
TAN, tumor-associated neutrophils 
TCR, T cell receptor 
TIL, tumor-infiltrating lymphocytes 
Treg, regulatory T lymphocytes 
  
Table 2. Therapeutic strategies targeting tumor microenvironment in iCCA. 
Cell compartment Compound Molecular target Therapeutic Effects 
CAF Navitoclax Bcl-2, Bcl-xL, Bcl-w Reduction in both tumor 
growth, and peritoneal/lymph 
node metastasisation (animal 
models) 
CAF A-1331852 Bcl-xL Reduction in biliary fibrosis 
(animal model) 
TIL Pembrolizumab PD-1 Stimulation of immune system 
leading to reduction in tumor 
growth (human) 
TIL Nivolumab PD-1 Stimulation of immune system 
leading to reduction in tumor 
growth (human)  
Endothelial cell Bevacizumab Anti-VEGF Reduction in tumor growth 
(human) 
Endothelial cell Sorafenib VEGFR, c-KIT and 
PDGFR-α 
Reduction in tumor growth 
(animal model),  
No effects (human)  
Lymphatic 
endothelial cell 




CAF, cancer-associated fibroblasts 
c-KIT, proto-oncogene, receptor tyrosine kinase 
PDGFR, platelet-derived growth factor receptor 
PD-1, programmed cell death protein-1 
TIL, tumor-infiltrating lymphocytes 
VEGF, vascular endothelial growth factor 
VEGFR, vascular endothelial growth factor receptor 
 
